Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

PURPOSE: Myelofibrosis is a myeloid malignancy associated with anemia, splenomegaly, and constitutional symptoms. Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor. PATIENTS AND METHODS: In a multicente...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Pardanani, Animesh, Gotlib, Jason R., Jamieson, Catriona, Cortes, Jorge E., Talpaz, Moshe, Stone, Richard M., Silverman, Michael H., Gilliland, D. Gary, Shorr, Jolene, Tefferi, Ayalew
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2011
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979099/
https://ncbi.nlm.nih.gov/pubmed/21220608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.8021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars